Similarly, baicalein inhibits glycolytic enzymes, including hexokinase 2 (HK2), lactate dehydrogenase A (LDH-A), and pyruvate dehydrogenase kinase 1 (PDK1), by activating phosphatase and tensin homolog (PTEN) and suppressing Akt/HIF-1α signaling, thereby reducing glycolytic flux and sensitizing GC cells to overcome 5-FU resistance in GC cells [89]. The gene discussed is LDHA; the disease is gastric cancer.